Clinical, Cosmetic and Investigational Dermatology (Oct 2022)
Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
Abstract
Abdullah Muqrin Al Muqrin,1 Abdulaziz A Alghamdi,1 Ziad M AlShaalan2 1Dermatology, Prince Mohammed Medical City, Skaka, AlJouf, Saudi Arabia; 2Department of Internal Medicine, College of Medicine, Jouf University, Skakak, AlJouf, Saudi ArabiaCorrespondence: Abdullah Muqrin Al Muqrin, Dermatology, Prince Mohammed Medical City, Skaka City, 72345, AlJouf, Saudi Arabia, Tel +96654777446, Email [email protected]: Palmoplantar psoriasis, a clinical variant of plaque psoriasis, has a significant impact by causing deterioration in the social and functional aspects of patients’ lives. Numerous therapeutic interventions are available for palmoplantar psoriasis. Although emerging biological agents have had an enormous positive impact on chronic plaque psoriasis, studies assessing their effectiveness in the palmoplantar phenotype are limited in the literature. We therefore present a case report of a patient with a 10-year history of palmoplantar psoriasis, which has significantly impacted her occupational life. She was treated with Risankizumab, showing a significant and rapid improvement in her symptoms. We believe that Risankizumab could be one of the most effective therapeutic interventions in the clinical context where rapid clearance of palmoplantar psoriasis is required.Keywords: psoriasis, Risankizumab, palmoplantar, rapid onset, biologic, biological agent
